NicOx partners with Bausch & Lomb for its candidate glaucoma drug

Article

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

B&L will also be able to consider development and marketing of other products containing NCX 116 under the terms of the agreement. Phase II trials have been completed and clinical trials in patients with glaucoma and ocular hypertension are underway.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
An illustration of a brain beneath a magnifying glass. Concept image for neuroophthalmological exam and ocular symptom paediatric neurology concept. Image credit: ©meeboonstudio – stock.adobe.com

Vision- and life-threatening neuro-ophthalmological presentations

Lorcan Butler, BSc (Hons), MCOptom, Prof Cert Paed Eye Care
April 25th 2025
Article

Paediatric diagnoses of juvenile idiopathic intracranial hypertension, optic neuritis and Horner syndrome

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A young boy with glasses reading a book. Concept image for atropine drop paediatric myopia treatment approval in India. Image credit: ©WESTOCK – stock.adobe.com

ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)

Hattie Hayes;Emily Kaiser Maharjan;Jordana Joy
April 23rd 2025
Article

According to a press release, Myatro XL is the first 0.05% atropine eye drop for paediatric myopia control.

A red light with an alarm symbol. It reads "SOS." Concept image for emergency, medical emergency, neurology and ophthalmology referral. Image credit: ©Nicole Kwiatkowski – stock.adobe.com

Investigating causes of diplopia to minimise morbidity and mortality

Lynda Charters
April 23rd 2025
Article

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions

A photo of a boardroom with a presenter's projector screen, and easel, and many chairs. Concept image for Beth Marsh appointed CCO chief commercial officer of Neurotech Pharmaceuticals, ophthalmic industry news update. Image credit: ©nnpp's Images – canva.com

Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch

Kassi Filkins
April 22nd 2025
Article

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

A series of gears with arrows pointing right in the center of each one. Concept image for five-step approach to dry eye disease. Image credit: ©Cagkan – stock.adobe.com

New trends in the diagnosis of dry eye disease: A patient-centric approach

Marc Labetoulle, MD, PhD
April 21st 2025
Article

A five-step approach to personalise and simplify treatment, leading to higher efficacy

© 2025 MJH Life Sciences

All rights reserved.